TABLE 2.
Effects of infection and antifungal treatment for guinea pigs inoculated with molds i.v.
| Organism (inoculum [CFU/kg]) and treatment and dose (mg/kg) | No. of animals infected | MST ± SEM (days) | % Survivors on day 12 | % Negative organs |
|---|---|---|---|---|
| A. flavus 01 (2.5 × 10) | ||||
| Placebo (0) | 15 | 5.9 ± 0.5 | 0 | 0 |
| Amphotericin B | ||||
| 0.31 | 5 | 3.8 ± 0.2 | 0 | 0 |
| 0.63 | 5 | 4.2 ± 0.2 | 0 | 0 |
| 1.25 | 5 | 4.4 ± 0.3 | 0 | 0 |
| 2.5 | 5 | 4.6 ± 0.7 | 0 | 0 |
| Itraconazole | ||||
| 2.5 | 15 | 9.3 ± 1.0 | 67 | 18 |
| 5.0 | 15 | 9.6 ± 1.0 | 67 | 27 |
| 10 | 15 | 11.3 ± 0.5 | 87 | 33 |
| 20 | 15 | 11.7 ± 0.2 | 87 | 47 |
| A. fumigatus 10 (1 × 107) | ||||
| Placebo (0) | 15 | 6.7 ± 0.8 | 13 | 3 |
| Amphotericin B | ||||
| 0.31 | 10 | 11.4 ± 0.3 | 70 | 25 |
| 0.63 | 10 | 11.4 ± 0.4 | 80 | 35 |
| 1.25 | 10 | 10.9 ± 0.8 | 80 | 38 |
| 2.5 | 10 | 11.1 ± 0.9 | 90 | 45 |
| Itraconazole | ||||
| 2.5 | 5 | 10.6 ± 1.0 | 60 | 25 |
| 5.0 | 5 | 10.6 ± 1.6 | 80 | 50 |
| 10 | 5 | 12.0 ± 0.0 | 100 | 70 |
| 20 | 5 | 11.4 ± 0.4 | 60 | 65 |
| P. boydii 24 (5 × 107) | ||||
| Placebo (0) | 10 | 12.0 ± 0.0 | 100 | 0 |
| Amphotericin B | ||||
| 0.31 | ND | ND | ND | ND |
| 0.63 | 5 | 12.0 ± 0.9 | 100 | 15 |
| 1.25 | 5 | 11.2 ± 0.0 | 80 | 5 |
| 2.5 | 5 | 12.0 ± 0.0 | 100 | 15 |
| Itraconazole | ||||
| 2.5 | 5 | 12.0 ± 0.0 | 100 | 0 |
| 5.0 | 10 | 12.0 ± 0.0 | 100 | 5 |
| 10 | 10 | 12.0 ± 0.0 | 100 | 5 |
| 20 | 10 | 11.7 ± 0.3 | 90 | 0 |
| P. boydii 25 (5 × 107) | ||||
| Placebo (0) | 10 | 12.0 ± 0.0 | 100 | 0 |
| Amphotericin B | ||||
| 0.31 | 5 | 12.0 ± 0.0 | 100 | 0 |
| 0.63 | 10 | 12.0 ± 0.0 | 100 | 0 |
| 1.25 | 10 | 12.0 ± 0.0 | 100 | 0 |
| 2.5 | 10 | 12.0 ± 0.0 | 100 | 0 |
| Itraconazole | ||||
| 2.5 | ND | ND | ND | ND |
| 5.0 | 5 | 12.0 ± 0.0 | 100 | 0 |
| 10 | 5 | 12.0 ± 0.0 | 100 | 0 |
| 20 | 5 | 11.4 ± 0.7 | 80 | 0 |
| R. arrhizus 26 (2.5 × 107) | ||||
| Placebo (0) | 5 | 3.0 ± 0.6 | 0 | 0 |
| Amphotericin B | ||||
| 0.31 | 5 | 5.4 ± 0.3 | 0 | 0 |
| 0.63 | 5 | 6.6 ± 1.6 | 20 | 0 |
| 1.25 | 5 | 6.2 ± 1.7 | 20 | 0 |
| 2.5 | 5 | 5.0 ± 0.7 | 0 | 0 |
| Itraconazole | ||||
| 2.5 | 5 | 3.2 ± 0.4 | 0 | 0 |
| 5.0 | 5 | 3.0 ± 0.4 | 0 | 0 |
| 10 | 5 | 3.0 ± 0.7 | 0 | 0 |
| 20 | 5 | 3.8 ± 0.7 | 0 | 0 |
| R. arrhizus 27 (2.5 × 107) | ||||
| Placebo (0) | 10 | 3.9 ± 0.3 | 0 | 0 |
| Amphotericin B | 5 | 5.0 ± 1.0 | 0 | 0 |
| 0.31 | 5 | 6.8 ± 1.7 | 20 | 0 |
| 0.63 | 5 | 5.6 ± 2.9 | 20 | 0 |
| 2.5 | 5 | 7.2 ± 2.8 | 20 | 0 |
| Itraconazole | ||||
| 2.5 | 5 | 3.6 ± 0.3 | 0 | 0 |
| 5.0 | 5 | 3.8 ± 0.2 | 0 | 0 |
| 10 | 5 | 3.4 ± 0.3 | 0 | 0 |
| 20 | 5 | 4.6 ± 0.4 | 0 | 0 |
a
Results are for daily i.p. treatments with 40% cyclodextrin placebo and with amphotericin B and itraconazole at the indicated doses. MST, mean survival time; ND, not determined.